Performance Analytics · Biotech & Life Sciences
Performance Analytics for Biotech & Life Sciences
Marketing measurement, MMM, and incrementality testing to prove ROAS at the channel and creative level. Investor relations, scientific communications, and growth marketing for biotech, pharma, medtech, and life sciences companies.
Book a 15-min strategy callThe Biotech & Life Sciences context
What performance analytics means for biotech & life sciences companies
Biotech marketing in 2026 must respect SEC fair disclosure rules, FDA promotional restrictions, clinical trial blackout periods, and MLR (Medical/Legal/Regulatory) review processes. Long timelines (pre-clinical to commercial: 7-15 years) require sustained narrative investment without short-term traffic metrics as proof.
Empire325's measurement practice delivers marketing mix modeling (MMM), incrementality experiments, and conversion-lift studies. We answer the question CFOs actually ask: which marketing dollars are driving revenue, and which would we be fine without.
Biotech & Life Sciences is a regulated sector, which materially changes how performance analytics engagements have to be structured. Empire325 operates within the applicable compliance framework (U.S. Food and Drug Administration guidance, supervisory review, and documented approval workflows) rather than around it. Programs are co-designed with your compliance counsel and chief compliance officer so that creative, distribution, measurement, and reporting all survive an audit. This is materially different from generic agency engagements that treat compliance as an afterthought and produce campaigns that get retroactively pulled or restricted.
For the canonical industry framing, see U.S. Food and Drug Administration — Empire325 references that source-of-truth when building the measurement, attribution, and compliance baseline for every biotech & life sciences performance analytics engagement. The methodology layer above it draws on Google Analytics Developers and our own production patterns from prior biotech & life sciences engagements.
Capabilities
Performance Analytics capabilities for biotech & life sciences clients
Why Empire325
Why Empire325 for biotech & life sciences performance analytics
Empire325 biotech marketing combines IR, scientific communications, KOL engagement, and commercial-readiness marketing — built alongside your regulatory and legal counsel. Scientific accuracy under MLR review, Reg-FD-aligned investor communications.
Measured outcomes
What biotech & life sciences clients achieve
Channel-level incremental ROAS
10-40% improved budget allocation
Causal proof for board / CFO conversations
Continuous optimization based on lift
FAQ — Performance Analytics for Biotech & Life Sciences
Does Empire325 provide performance analytics for biotech & life sciences companies?
Yes. Empire325 delivers performance analytics specifically calibrated for biotech & life sciences companies. Empire325 biotech marketing combines IR, scientific communications, KOL engagement, and commercial-readiness marketing — built alongside your regulatory and legal counsel. Scientific accuracy under MLR review, Reg-FD-aligned investor communications.
What makes performance analytics different for biotech & life sciences vs. other industries?
Biotech marketing in 2026 must respect SEC fair disclosure rules, FDA promotional restrictions, clinical trial blackout periods, and MLR (Medical/Legal/Regulatory) review processes. Long timelines (pre-clinical to commercial: 7-15 years) require sustained narrative investment without short-term traffic metrics as proof. Empire325 applies performance analytics methodology with these industry-specific constraints and opportunities built in — not as an afterthought.
How much does performance analytics cost for biotech & life sciences companies?
Performance Analytics engagements for biotech & life sciences clients typically range from $10K–$60K monthly retainers depending on scope, team size, and market reach. Empire325 provides written scoping after a 30-minute discovery call. Most engagements deliver first measurable outcomes within 60–90 days.
Why choose Empire325 for biotech & life sciences performance analytics?
Empire325 biotech marketing combines IR, scientific communications, KOL engagement, and commercial-readiness marketing — built alongside your regulatory and legal counsel. Scientific accuracy under MLR review, Reg-FD-aligned investor communications. Empire325's performance analytics practice combines technical depth with biotech & life sciences-specific domain knowledge — so the work lands in your market, not just in a generic framework.
References & further reading
Sources cited on this performance analytics for biotech & life sciences page
- Google Analytics Developers — Google Analytics 4 measurement protocol and event-data model documentation.
- U.S. Food and Drug Administration — FDA Center for Drug Evaluation and Research promotional-communications guidance.
- Harvard Business Review — Harvard Business Review research on industry-specific marketing strategy and ROI benchmarks.
Need performance analytics for your biotech & life sciences company?
15-minute strategy call. No deck, no pitch — specific recommendations based on your context.
Book a 15-min strategy call